Navigation Links
Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
Date:10/7/2009

NEW HAVEN, Conn., Oct. 7 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of multi-antibiotic resistant infections, today announced that Rib-X Co-Founder and Chair of the Scientific Advisory Board, Sterling Professor of Molecular Biophysics and Biochemistry at Yale University and a Howard Hughes Medical Institute Investigator, Thomas A. Steitz, Ph.D., has been awarded the Nobel Prize in Chemistry for 2009 by The Royal Swedish Academy of Sciences.

Dr. Steitz shares the prize with Venkatraman Ramakrishnan of the MRC Laboratory of Molecular Biology, Cambridge, United Kingdom, and Ada E. Yonath, Weizmann Institute of Science, Rehovot, Israel. All three were praised for their work on using "X-ray crystallography to map the position for each and every one of the hundreds of thousands of atoms that make up the ribosome." Dr. Ramakrishnan is also on Rib-X's Scientific Advisory Board.

"Rib-X would like to extend its congratulations to Drs. Steitz, Ramakrishnan and Yonath on receiving the most esteemed award for scientific endeavors and accomplishments," said Dr. Susan Froshauer, President and Chief Executive Officer, Rib-X. "As one of our co-founders, Dr. Steitz recognized the importance of the ribosome early on, and he continues to perform a valuable role to us as the Chair of the Scientific Advisory Board."

"I am excited by the prospect that our work on the structure of the ribosome and mechanisms of antibiotic binding is leading to potential new chemical classes which have the potential to treat a wide variety of multi-drug resistant bacterial infections," commented Dr. Steitz.

Dr. Peter Moore, Sterling Professor of Chemistry at Yale University and Dr. Harry Noller, Robert Louis Sinsheimer Professor of Molecular Biology at the University of California, Santa Cruz, also co-founders and part of Rib-X's Scientific Advisory
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
6. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
7. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013 The potential of ... delivery of therapeutic agents has been receiving undeniable attention ... showing significant promise. The crucial formulation considerations for orally ... play a major role in the efficiency of pulmonary ... development of new formulation techniques and devices in recent ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de ... ), un destacado desarrollador y fabricante de herramientas ... la diagnosis y tratamiento de la enfermedad vascular ... del ensayo ADVISE ( Ad enosine V ... E valuation) II durante la sesión de ensayo ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. (OTC ... medical device company that develops and sells high performance ... its rights offering.  In addition, the concurrent temporary reduction ... expired on May 17, 2013. Nephros estimates ... from the rights offering.   A portion of the proceeds ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... SILVER SPRING, Md., May 9, 2011 /PRNewswire-USNewswire/ – CoMeD ... a Republican State Senator filed an amendment to regulate ... made it illegal to buy, sell, manufacture, deliver, import, ... 0.3 micrograms of organic or inorganic mercury per milliliter ...
... May 9, 2011 TriReme Medical, Inc. (TriReme), a ... treatment of complex vascular disease, announced today the appointment ... their Board of Directors. Mr. Bose, Founder ... Singapore and was until recently Company Group Chairman at ...
Cached Medicine Technology:Florida Legislature Refuses to Limit Mercury in Vaccines 2Florida Legislature Refuses to Limit Mercury in Vaccines 3TriReme Medical Lines Up Asian Strategy With Key Appointment of New Board Members 2
(Date:5/24/2013)... of five medical students have an unconscious bias against ... authors, from Wake Forest Baptist Medical Center, noted the ... of obesity. They concluded that teaching medical students to ... the millions of Americans who are overweight or obese. ... relationship, and even a patient,s willingness or desire to ...
(Date:5/24/2013)... fractional flow reserve (FFR) using pressure wire assessment ... leads to significant changes in the management of ... a study reported at EuroPCR 2013. , The ... strategy at coronary angiography for diagnosis of chest ... assessment of FFR in all the main coronary ...
(Date:5/24/2013)... Transcatheter aortic valve implantation (TAVI) is effective and safe ... first results from a multicentre Asian registry reported at ... become a treatment option for selected patients with symptomatic ... from North American or European centres," Paul Chiam, senior ... the conference. He explained that it is unknown whether ...
(Date:5/24/2013)... A new discovery at Oregon Health & Science University ... reacts when infected with the highly evasive HIV virus ... been utilizing this unique approach to develop its own ... results in animal studies. This latest research finding will ... the journal Science . , "A major ...
(Date:5/24/2013)... 24, 2013 The producers of Health ... for Charlotte, North Carolina. It is one of the largest ... companies. The city is populated with more than a million ... residents in both North and South Carolina. Viewers who are ... can tune into WAXN-TV 64 Eyewitness News during the month ...
Breaking Medicine News(10 mins):Health News:Many Medical Students Have Anti-Fat Bias, Study Finds 2Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:Registry confirms TAVI efficacy and safety in Asian patients 2Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2Health News:Health Briefs TV Presents May Air Dates for Charlotte, North Carolina 2
... rankings aim to help families choose best option , , ... Medicare and Medicaid Services unveiled an updated Web site ... for elderly Americans and their families. , The updated ... similar to that used for hotels and motels, to ...
... NY, December 18, 2008Medical acupuncture, which is acupuncture performed ... school, is being used increasingly for pain control. Richard ... , a peer-reviewed journal ( www.liebertpub.com/acu ) and the ... is at the forefront of these efforts in the ...
... the European Association of Urology (EAU) will be held from ... (SE). The scientific programme covers the whole range of the ... it will all be discussed at the congress. ... are extended to a full-day event called EAU International Day ...
... study,s design may be to blame for desmoteplase,s poor showing, ... experimental clot-busting drug derived from the saliva of the vampire ... trial. , But hope for the drug, called desmoteplase, remains ... large enough to provide clear results. , "The sample size ...
... who suffer from thinning hair and hair loss with an all-natural ... all-natural DHT blockers with no side effects. , ... ... offering patients who suffer from thinning hair and hair loss with ...
... drug eluting stents (DES) stents coated with medication to ... angioplasty had better outcomes one year later than patients with ... published in CMAJ http://www.cmaj.ca/press/080050.pdf . , Mortality ... stents was significantly lower than for those with bare metal ...
Cached Medicine News:Health News:Government Launches Nursing Home Rating System 2Health News:Government Launches Nursing Home Rating System 3Health News:Annual Congress European Association of Urology: highlights in Stockholm 2Health News:Bat Saliva-Based Stroke Drug Disappoints in Trial 2Health News:Bat Saliva-Based Stroke Drug Disappoints in Trial 3Health News:Your Chemist Shop Offers Patients a Revolutionary Alternative to Other Hair Loss Treatments for Both Men and Women 2
The 7700 Reciprocating Saw completes the large power system with our simple twist-lock blade hub and selection of saw blades....
The 7500 Drill/Reamer operates at two speeds for multiple applications, which is automatically controlled by the 16 different coupler attachments. The drill reamer can be used for, but is not limited...
... SmartDriver System consists of a pistol-grip handpiece ... with a wide range of couplers that ... orthopedic surgical applications., ,The Battery SmartDriver ... compared to the original Battery SmartDriver. The ...
... Meniscus Implant (CMI) is a type I ... irreparable meniscus tear or loss of meniscus ... procedure. The purpose of the CMI ... and return to a more vigorous lifestyle, ...
Medicine Products: